MME and hydrops fetalis: Despite statistical insignificance, the numerically higher event rates in the sacubitril-valsartan arm in the LIFE trial raised the possibility of a lack of efficacy with neprilysin inhibition in advanced HF patients with NYHA functional class IV symptoms.11